Wells Fargo downgraded Soleno Therapeutics (SLNO) to Equal Weight from Overweight with a price target of $53, down from $110. The firm cites Neurocrine’s (NBIX) pending acquisition of the company at $53 per share for the downgrade. The deal is expected to close in Q3, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Soleno’s VYKAT XR Real-World Study Adds Fuel to the Prader-Willi Investment Story
- Largest borrow rate increases among liquid names
- Soleno Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 3 Best Trending Stocks, According to Analysts – 4/7/2026